Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation (Q40000886)

16 September 2017

title

Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation (English)

1 reference

16 September 2017

author

Cornelis J. M. Melief

4

object named as

Cornelis J M Melief

1 reference

16 September 2017

Sjoerd H van der Burg

5

object named as

Sjoerd H van der Burg

1 reference

16 September 2017

3

Kees L Franken

1 reference

16 September 2017

Martijn S Bijker

1

1 reference

16 September 2017

Susan J F van den Eeden

2

1 reference

16 September 2017

Rienk Offringa

6

1 reference

16 September 2017

language of work or name

English

0 references

publication date

1 April 2008

1 reference

European Journal of Immunology

16 September 2017

published in

1 reference

16 September 2017

volume

38

1 reference

16 September 2017

issue

4

1 reference

16 September 2017

page(s)

1033-1042

1 reference

Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma

16 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737995

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737995

Dendritic Cells as Carriers for a Cytotoxic T-Lymphocyte Epitope-Based Peptide Vaccine in Protection Against a Human Papillomavirus Type 16-Induced Tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737995

Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737995

Cutting edge: prolonged antigen presentation after herpes simplex virus-1 skin infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737995

Dendritic cells are sufficient to cross-present self-antigens to CD8 T cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737995

CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737995

Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737995

Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737995

7 January 2021

CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737995

7 January 2021

Design and development of synthetic peptide vaccines: past, present and future

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737995

7 January 2021

Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737995

7 January 2021

Peptide vaccination with an anchor-replaced CTL epitope protects against human papillomavirus type 16-induced tumors expressing the wild-type epitope

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737995

7 January 2021

Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737995

7 January 2021

T cell priming versus T cell tolerance induced by synthetic peptides

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737995

7 January 2021

Heteroclitic immunization induces tumor immunity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737995

7 January 2021

Cancer immunotherapy: moving beyond current vaccines

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737995

7 January 2021

CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737995

7 January 2021

Induction of ovalbumin-specific cytotoxic T cells by in vivo peptide immunization

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737995

7 January 2021

Efficient MHC class I-peptide binding is required but does not ensure MHC class I-restricted immunogenicity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737995

7 January 2021

In vivo CTL induction with point-substituted ovalbumin peptides: immunogenicity correlates with peptide-induced MHC class I stability

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737995

7 January 2021

A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737995

7 January 2021

The use of carboxyfluorescein diacetate succinimidyl ester to determine the site, duration and cell type responsible for antigen presentation in vivo

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737995

7 January 2021

Antigen presentation and T cell stimulation by dendritic cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737995

7 January 2021

Pharmacokinetic differences between a T cell-tolerizing and a T cell-activating peptide

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737995

7 January 2021

B cells directly tolerize CD8(+) T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737995

7 January 2021

Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737995

7 January 2021

Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737995

7 January 2021

Inhibition of methylcholanthrene-induced carcinogenesis by an interferon gamma receptor-dependent foreign body reaction

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737995

7 January 2021

Introduction of soluble protein into the class I pathway of antigen processing and presentation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737995

7 January 2021

Identifiers

DOI

10.1002/EJI.200737995

1 reference

16 September 2017

1 reference